Drug intelligence / Profile preview

HN0190

Development stage: Preclinical
Lead developer: Phaeno Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

HN0190 is a small molecule antiviral drug candidate developed by Huinuo Biopharmaceutical Technology (also known as Phaenothera) for the treatment of Influenza A and B infections. The drug is designed to address seasonal influenza by inhibiting viral replication or entry, although its specific molecular target (such as neuraminidase or the polymerase complex) has not been publicly disclosed in the company's primary pipeline materials. As of early 2024, HN0190 is in the IND-enabling (preclinical) stage of development, with the company preparing for clinical trial applications.

Beyond the preview

Go deeper on HN0190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN0190.

Explore the full profile